Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
46
SMMT Quote, Financials, Valuation and Earnings
Last price:
$18.57
Seasonality move
:
26.83%
Day range:
$18.08 - $19.10
52-week range:
$15.55 - $36.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21,812.02x
P/B ratio:
70.90x
Volume:
2.4M
Avg. volume:
2.6M
1-year change:
4.51%
Market cap:
$13.6B
Revenue:
--
EPS (TTM):
-$1.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SMMT
Summit Therapeutics, Inc.
|
$77.1M | -$0.06 | -- | -75.35% | $32.06 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 97.59% | -58.59% | $492.17 |
|
CVS
CVS Health Corp.
|
$98.8B | $1.36 | 4.88% | -25.78% | $91.84 |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$72.8M | -$0.26 | 11.66% | -35.2% | $8.25 |
|
MRK
Merck & Co., Inc.
|
$17B | $2.35 | 5.81% | 38.62% | $106.62 |
|
UNH
UnitedHealth Group, Inc.
|
$113.6B | $6.58 | 12.53% | -65.23% | $388.52 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SMMT
Summit Therapeutics, Inc.
|
$18.31 | $32.06 | $13.6B | -- | $0.00 | 0% | 21,812.02x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$458.12 | $492.17 | $60.5B | 1,904.86x | $0.00 | 0% | 18.79x |
|
CVS
CVS Health Corp.
|
$75.63 | $91.84 | $96B | 197.67x | $0.67 | 3.52% | 0.24x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$2.20 | $8.25 | $873.3M | -- | $0.00 | 0% | 2.91x |
|
MRK
Merck & Co., Inc.
|
$99.72 | $106.62 | $247.5B | 13.19x | $0.81 | 3.25% | 3.93x |
|
UNH
UnitedHealth Group, Inc.
|
$330.91 | $388.52 | $299.8B | 17.27x | $2.21 | 2.61% | 0.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SMMT
Summit Therapeutics, Inc.
|
2.75% | -0.211 | 0.04% | 3.68x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
CVS
CVS Health Corp.
|
52.85% | 0.779 | 85.22% | 0.49x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.96% | -0.206 | 6.28% | 2.92x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.025 | 20.79% | 1.06x |
|
UNH
UnitedHealth Group, Inc.
|
45.55% | -0.149 | 24.83% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SMMT
Summit Therapeutics, Inc.
|
-$42K | -$234.2M | -274.32% | -283.98% | -- | -$95.1M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
CVS
CVS Health Corp.
|
$13.8B | $3B | 0.27% | 0.57% | 2.88% | $98M |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$20M | -$89.8M | -50.35% | -54.43% | -133.06% | -$89.5M |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
UNH
UnitedHealth Group, Inc.
|
-- | $4.3B | 9.95% | 17.57% | 2.85% | $5.1B |
Summit Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SMMT or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of 20.1%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital SMMTSummit Therapeutics, Inc.-- -$0.31 $197.7M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About SMMT or ALNY?
Summit Therapeutics, Inc. has a consensus price target of $32.06, signalling upside risk potential of 75.08%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $492.17 which suggests that it could grow by 7.43%. Given that Summit Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMMTSummit Therapeutics, Inc.11 2 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is SMMT or ALNY More Risky?
Summit Therapeutics, Inc. has a beta of -1.523, which suggesting that the stock is 252.256% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock SMMT or ALNY?
Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMMT or ALNY?
Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,904.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 18.79x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMMTSummit Therapeutics, Inc.21,812.02x -- -- -$231.8M ALNYAlnylam Pharmaceuticals, Inc.18.79x 1,904.86x $1.2B $251.1M
-
Which has Higher Returns SMMT or CVS?
CVS Health Corp. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of -3.88%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat CVS Health Corp.'s return on equity of 0.57%.
Company Gross Margin Earnings Per Share Invested Capital SMMTSummit Therapeutics, Inc.-- -$0.31 $197.7M CVSCVS Health Corp.13.43% -$3.13 $154.9B -
What do Analysts Say About SMMT or CVS?
Summit Therapeutics, Inc. has a consensus price target of $32.06, signalling upside risk potential of 75.08%. On the other hand CVS Health Corp. has an analysts' consensus of $91.84 which suggests that it could grow by 21.43%. Given that Summit Therapeutics, Inc. has higher upside potential than CVS Health Corp., analysts believe Summit Therapeutics, Inc. is more attractive than CVS Health Corp..
Company Buy Ratings Hold Ratings Sell Ratings SMMTSummit Therapeutics, Inc.11 2 0 CVSCVS Health Corp.17 5 0 -
Is SMMT or CVS More Risky?
Summit Therapeutics, Inc. has a beta of -1.523, which suggesting that the stock is 252.256% less volatile than S&P 500. In comparison CVS Health Corp. has a beta of 0.481, suggesting its less volatile than the S&P 500 by 51.936%.
-
Which is a Better Dividend Stock SMMT or CVS?
Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health Corp. offers a yield of 3.52% to investors and pays a quarterly dividend of $0.67 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. CVS Health Corp. pays out 72.76% of its earnings as a dividend. CVS Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SMMT or CVS?
Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than CVS Health Corp. quarterly revenues of $102.9B. Summit Therapeutics, Inc.'s net income of -$231.8M is higher than CVS Health Corp.'s net income of -$4B. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while CVS Health Corp.'s PE ratio is 197.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 0.24x for CVS Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMMTSummit Therapeutics, Inc.21,812.02x -- -- -$231.8M CVSCVS Health Corp.0.24x 197.67x $102.9B -$4B
-
Which has Higher Returns SMMT or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of -135.28%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.
Company Gross Margin Earnings Per Share Invested Capital SMMTSummit Therapeutics, Inc.-- -$0.31 $197.7M IOVAIovance Biotherapeutics, Inc.29.61% -$0.25 $754.8M -
What do Analysts Say About SMMT or IOVA?
Summit Therapeutics, Inc. has a consensus price target of $32.06, signalling upside risk potential of 75.08%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 275%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Summit Therapeutics, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Summit Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMMTSummit Therapeutics, Inc.11 2 0 IOVAIovance Biotherapeutics, Inc.6 4 1 -
Is SMMT or IOVA More Risky?
Summit Therapeutics, Inc. has a beta of -1.523, which suggesting that the stock is 252.256% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.288%.
-
Which is a Better Dividend Stock SMMT or IOVA?
Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMMT or IOVA?
Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 2.91x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMMTSummit Therapeutics, Inc.21,812.02x -- -- -$231.8M IOVAIovance Biotherapeutics, Inc.2.91x -- $67.5M -$91.3M
-
Which has Higher Returns SMMT or MRK?
Merck & Co., Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of 33.68%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital SMMTSummit Therapeutics, Inc.-- -$0.31 $197.7M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About SMMT or MRK?
Summit Therapeutics, Inc. has a consensus price target of $32.06, signalling upside risk potential of 75.08%. On the other hand Merck & Co., Inc. has an analysts' consensus of $106.62 which suggests that it could grow by 6.92%. Given that Summit Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMMTSummit Therapeutics, Inc.11 2 0 MRKMerck & Co., Inc.14 13 0 -
Is SMMT or MRK More Risky?
Summit Therapeutics, Inc. has a beta of -1.523, which suggesting that the stock is 252.256% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.
-
Which is a Better Dividend Stock SMMT or MRK?
Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.81 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SMMT or MRK?
Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 3.93x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMMTSummit Therapeutics, Inc.21,812.02x -- -- -$231.8M MRKMerck & Co., Inc.3.93x 13.19x $17.2B $5.8B
-
Which has Higher Returns SMMT or UNH?
UnitedHealth Group, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of 2.25%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat UnitedHealth Group, Inc.'s return on equity of 17.57%.
Company Gross Margin Earnings Per Share Invested Capital SMMTSummit Therapeutics, Inc.-- -$0.31 $197.7M UNHUnitedHealth Group, Inc.-- $2.59 $185.9B -
What do Analysts Say About SMMT or UNH?
Summit Therapeutics, Inc. has a consensus price target of $32.06, signalling upside risk potential of 75.08%. On the other hand UnitedHealth Group, Inc. has an analysts' consensus of $388.52 which suggests that it could grow by 17.41%. Given that Summit Therapeutics, Inc. has higher upside potential than UnitedHealth Group, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than UnitedHealth Group, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMMTSummit Therapeutics, Inc.11 2 0 UNHUnitedHealth Group, Inc.12 6 2 -
Is SMMT or UNH More Risky?
Summit Therapeutics, Inc. has a beta of -1.523, which suggesting that the stock is 252.256% less volatile than S&P 500. In comparison UnitedHealth Group, Inc. has a beta of 0.428, suggesting its less volatile than the S&P 500 by 57.182%.
-
Which is a Better Dividend Stock SMMT or UNH?
Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group, Inc. offers a yield of 2.61% to investors and pays a quarterly dividend of $2.21 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. UnitedHealth Group, Inc. pays out 52.75% of its earnings as a dividend. UnitedHealth Group, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SMMT or UNH?
Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than UnitedHealth Group, Inc. quarterly revenues of $113.2B. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than UnitedHealth Group, Inc.'s net income of $2.5B. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while UnitedHealth Group, Inc.'s PE ratio is 17.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 0.70x for UnitedHealth Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMMTSummit Therapeutics, Inc.21,812.02x -- -- -$231.8M UNHUnitedHealth Group, Inc.0.70x 17.27x $113.2B $2.5B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 60.69% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 7.84% over the past day.
Sell
13
PSN alert for Dec 8
Parsons Corp. [PSN] is down 5.82% over the past day.
